#VisualAbstract Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer
Click to read the study in NEJM.
©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
RelatedReports
